Anti-Human P-Selectin/CD62P Reference Antibody (Crizanlizumab, RUO)

Description: Crizanlizumab (BS10641) is a research-grade recombinant antibody targeting CD62P. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG2-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 6.06mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Leukocyte-endothelialcelladhesionmolecule3,Plateletactivationdependentgranule-externalmembraneprotein,Granulemembraneprotein140,GMP-140,CD62P,SELP,GRMP,PADGEM,CD62antigen-likefamilymemberP,LECAM3,P-selectin,GMRP
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: SelG1,CAS:1690318-25-2
Background: P-selectin (CD62P/SELP) is a ~90 kDa protein. Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with SELPLG. Mediates cell-cell interactions and cell adhesion via the interaction with integrin alpha-IIb/beta3 (ITGA2B:ITGB3) and integrin alpha-V/beta-3 (ITGAV:ITGB3).
References:
1. Takada, YK. et al. (2023) Life science alliance 6. PMID: 37184585
Note: For research use only. Not suitable for clinical or therapeutic use.